MK-0616 (Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015)
Conditions: Arteriosclerosis; Hypercholesterolaemia Interventions: Drug: MK-0616; Drug: Placebo Sponsor: Merck Sharp & Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 24, 2023 Category: Research Source Type: clinical trials
Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies
Conditions: Dyslipidemias; Hypercholesterolemia; Familial Hypercholesterolemia; ASCVD; High Cholesterol Interventions: Combination Product: Combination Therapy; Drug: Monotherapy obicetrapib; Drug: Monotherapy ezetimibe; Other: Combination Therapy placebo; Other: Obicetrapib Placebo; Other: Ezetimibe Placebo Sponsor: NewAmsterdam Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 22, 2023 Category: Research Source Type: clinical trials